Vascular Biogenics Analysis
| VBLTDelisted Stock | USD 0.28 0.01 3.45% |
Vascular Biogenics is overvalued with Real Value of 0.22 and Hype Value of 0.28. The main objective of Vascular Biogenics delisted stock analysis is to determine its intrinsic value, which is an estimate of what Vascular Biogenics is worth, separate from its market price. There are two main types of Vascular Biogenics' stock analysis: fundamental analysis and technical analysis.
The Vascular Biogenics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Vascular Biogenics is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Vascular Stock trading window is adjusted to America/New York timezone.
Vascular |
Vascular Stock Analysis Notes
About 13.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 0.35. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vascular Biogenics recorded a loss per share of 0.18. The entity had not issued any dividends in recent years. Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modiin, Israel. Vascular Biogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people. For more information please call Pr MD at 972 8 993 5000 or visit https://www.vblrx.com.Vascular Biogenics Investment Alerts
| Vascular Biogenics is not yet fully synchronised with the market data | |
| Vascular Biogenics has some characteristics of a very speculative penny stock | |
| Vascular Biogenics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 658 K. Net Loss for the year was (32.3 M) with profit before overhead, payroll, taxes, and interest of 554 K. | |
| Vascular Biogenics currently holds about 34.15 M in cash with (31.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.49, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 13.0% of the company outstanding shares are owned by insiders |
Vascular Biogenics Upcoming and Recent Events
| 13th of November 2023 Upcoming Quarterly Report | View | |
| 30th of September 2023 Next Fiscal Quarter End | View |
Vascular Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.83 M.Vascular Biogenics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vascular Biogenics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vascular Biogenics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vascular Biogenics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Samuel Backenroth over a year ago Exercise or conversion by Samuel Backenroth of 525000 shares of Vascular Biogenics subject to Rule 16b-3 |
Vascular Biogenics Outstanding Bonds
Vascular Biogenics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Vascular Biogenics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Vascular bonds can be classified according to their maturity, which is the date when Vascular Biogenics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View |
Vascular Biogenics Predictive Daily Indicators
Vascular Biogenics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Vascular Biogenics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
About Vascular Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Vascular Biogenics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Vascular shares will generate the highest return on investment. We also built our delisted stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Delisted Stock such as Vascular Biogenics. By using and applying Vascular Stock analysis, traders can create a robust methodology for identifying Vascular entry and exit points for their positions.
Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modiin, Israel. Vascular Biogen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Vascular Biogenics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run ETF Categories Now
ETF CategoriesList of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
| All Next | Launch Module |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Other Consideration for investing in Vascular Stock
If you are still planning to invest in Vascular Biogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vascular Biogenics' history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |